A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFN drugs in the treatment of multiple sclerosis
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFN drugs in the treatment of multiple sclerosis
Authors
Keywords
-
Journal
HUMAN MOLECULAR GENETICS
Volume 24, Issue 11, Pages 3192-3205
Publisher
Oxford University Press (OUP)
Online
2015-02-27
DOI
10.1093/hmg/ddv071
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Interferon-Stimulated Genes: A Complex Web of Host Defenses
- (2014) William M. Schneider et al. Annual Review of Immunology
- Enhancedin VivoEfficacy of a Type I Interferon Superagonist with Extended Plasma Half-life in a Mouse Model of Multiple Sclerosis
- (2014) Daniel Harari et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- How Type I Interferons Work in Multiple Sclerosis and Other Diseases: Some Unexpected Mechanisms
- (2014) Anthony T. Reder et al. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
- New treatments for multiple sclerosis: at what long-term risk?
- (2014) Michelle H Cameron et al. LANCET NEUROLOGY
- Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk
- (2014) Katrin D. Mayer-Barber et al. NATURE
- FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS
- (2014) Yawei Liu et al. NATURE MEDICINE
- Bridging the Species Divide: Transgenic Mice Humanized for Type-I Interferon Response
- (2014) Daniel Harari et al. PLoS One
- Blood RNA profiling in a large cohort of multiple sclerosis patients and healthy controls
- (2013) Dorothee Nickles et al. HUMAN MOLECULAR GENETICS
- Double-Stranded RNA of Intestinal Commensal but Not Pathogenic Bacteria Triggers Production of Protective Interferon-β
- (2013) Tadaomi Kawashima et al. IMMUNITY
- Hope and Fear for Interferon: The Receptor-Centric Outlook on the Future of Interferon Therapy
- (2013) Serge Y. Fuchs JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
- In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: No
- (2013) Jan Hillert Multiple Sclerosis Journal
- WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013
- (2013) Jing Wang et al. NUCLEIC ACIDS RESEARCH
- Baseline Gene Expression Signatures in Monocytes from Multiple Sclerosis Patients Treated with Interferon-beta
- (2013) Marta F. Bustamante et al. PLoS One
- Ubiquitination-mediated regulation of interferon responses
- (2012) Serge Y. Fuchs GROWTH FACTORS
- Constitutive Type I Interferon Modulates Homeostatic Balance through Tonic Signaling
- (2012) Daniel J. Gough et al. IMMUNITY
- Priming of Natural Killer Cells by Nonmucosal Mononuclear Phagocytes Requires Instructive Signals from Commensal Microbiota
- (2012) Stephanie C. Ganal et al. IMMUNITY
- Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance
- (2012) Alexander Hundeshagen et al. Journal of Neuroinflammation
- Survival in MS
- (2012) D.S. Goodin et al. NEUROLOGY
- Two recombinant human interferon-beta 1a pharmaceutical preparations produce a similar transcriptional response determined using whole genome microarray analysis
- (2011) A.E. Sterin Prync et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- A Novel PEGylated Interferon Beta-1a for Multiple Sclerosis: Safety, Pharmacology, and Biology
- (2011) Xiao Hu et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis
- (2011) Xuan Feng et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Determinants of interferon β efficacy in patients with multiple sclerosis
- (2011) Joep Killestein et al. Nature Reviews Neurology
- Inflammatory signaling compromises cell responses to interferon alpha
- (2011) W-C HuangFu et al. ONCOGENE
- Search for Specific Biomarkers of IFNβ Bioactivity in Patients with Multiple Sclerosis
- (2011) Sunny Malhotra et al. PLoS One
- USP18-Based Negative Feedback Control Is Induced by Type I and Type III Interferons and Specifically Inactivates Interferon α Response
- (2011) Véronique François-Newton et al. PLoS One
- A type I interferon signature in monocytes is associated with poor response to interferon-β in multiple sclerosis
- (2009) M. Comabella et al. BRAIN
- The multiple sclerosis severity score (MSSS) predicts disease severity over time
- (2009) Andrew R. Pachner et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Alpha Interferon Induces Long-Lasting Refractoriness of JAK-STAT Signaling in the Mouse Liver through Induction of USP18/UBP43
- (2009) M. Sarasin-Filipowicz et al. MOLECULAR AND CELLULAR BIOLOGY
- Longitudinal system-based analysis of transcriptional responses to type I interferons
- (2009) D. J. Pappas et al. PHYSIOLOGICAL GENOMICS
- Genome-Wide Pharmacogenomic Analysis of the Response to Interferon Beta Therapy in Multiple Sclerosis
- (2008) Esther Byun et al. ARCHIVES OF NEUROLOGY
- Pharmacogenomics of Interferon-ß Therapy in Multiple Sclerosis: Baseline IFN Signature Determines Pharmacological Differences between Patients
- (2008) Lisa G. M. van Baarsen et al. PLoS One
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now